Co-Authors
This is a "connection" page, showing publications co-authored by Fengcai Zhu and Jingxin Li.
Connection Strength
1.577
-
Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med. 2021 06; 27(6):1062-1070.
Score: 0.941
-
Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. Signal Transduct Target Ther. 2021 02 02; 6(1):48.
Score: 0.232
-
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 02; 21(2):181-192.
Score: 0.228
-
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. Signal Transduct Target Ther. 2021 04 24; 6(1):165.
Score: 0.059
-
Understanding the phase separation characteristics of nucleocapsid protein provides a new therapeutic opportunity against SARS-CoV-2. Protein Cell. 2021 09; 12(9):734-740.
Score: 0.059
-
HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV. J Virol. 2021 01 28; 95(4).
Score: 0.058